US BANCORP \DE\ - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 125 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.2%.

Quarter-by-quarter ownership
US BANCORP \DE\ ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$8,630
-26.5%
1,000
-11.8%
0.00%
Q2 2023$11,737
-47.8%
1,134
-45.3%
0.00%
Q1 2023$22,503
+13.4%
2,074
+17.2%
0.00%
Q4 2022$19,848
+10.3%
1,7690.0%0.00%
Q3 2022$18,000
-21.7%
1,769
-30.6%
0.00%
Q2 2022$23,000
-8.0%
2,548
-1.1%
0.00%
Q1 2022$25,000
-10.7%
2,577
+0.2%
0.00%
Q4 2021$28,000
+2700.0%
2,573
+1626.8%
0.00%
Q3 2021$1,0000.0%149
+272.5%
0.00%
Q2 2021$1,0000.0%400.0%0.00%
Q1 2021$1,000
-50.0%
40
-65.5%
0.00%
Q4 2020$2,000
-50.0%
116
-38.3%
0.00%
Q2 2020$4,000
+100.0%
188
+150.7%
0.00%
Q1 2020$2,0000.0%750.0%0.00%
Q4 2019$2,000
+100.0%
750.0%0.00%
Q3 2019$1,0000.0%75
+82.9%
0.00%
Q4 2015$1,000
-96.6%
41
-98.5%
0.00%
Q3 2015$29,000
-17.1%
2,6970.0%0.00%
Q2 2015$35,000
-66.7%
2,697
-55.4%
0.00%
Q1 2015$105,000
+16.7%
6,041
+0.7%
0.00%
Q4 2014$90,000
+4400.0%
6,000
+6958.8%
0.00%
Q2 2014$2,000850.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q3 2022
NameSharesValueWeighting ↓
Madison Avenue Partners, LP 7,012,226$78,677,17613.94%
Irenic Capital Management LP 1,700,937$19,084,5139.15%
Weiss Asset Management LP 7,457,060$83,668,2133.41%
Newtyn Management, LLC 1,450,000$16,269,0003.36%
Palliser Capital (UK) Ltd 97,100$1,089,4622.65%
Chescapmanager LLC 850,988$9,5482.24%
Park West Asset Management LLC 1,920,324$21,546,0352.11%
Baupost Group 11,419,226$128,1242.09%
Saturn V Capital Management LP 141,339$1,334,3421.11%
Oasis Management Co Ltd. 296,960$3,331,8910.66%
View complete list of THERAVANCE BIOPHARMA INC shareholders